Inhibikase Reports $193.3M in Cash and Q3 Net Loss of $20.5M
Inhibikase reported $193.3M in cash, cash equivalents and marketable securities as of September 30, 2026. Its Q3 net loss was $20.5M, or $0.10 per share, versus $11.9M, or $0.13 per share, a year earlier.
Inhibikase reported $193.3M in cash, cash equivalents and marketable securities as of September 30, 2026. Q3 net loss was $20.5M, or $0.10 per share, versus $11.9M, or $0.13 per share, a year earlier.Material DetailsContext by AI AnalystThe results show a clinical-stage company funding an active Ph…